Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348209 | 0.86 | ALDH1A1 (0.51) | ALKBH5CYP1A2MAPTALDH1A1KMT2A | |
| SCHEMBL11478321 | 0.83 | ALKBH5 (0.66) | ALKBH5CYP1A2MAPTALDH1A1KMT2A | |
| SCHEMBL4338380 | 0.83 | MAPT (0.63) | ALKBH5MAPTALDH1A1KMT2AHTT | |
| SCHEMBL5675303 | 0.79 | ALKBH5 (0.65) | ALKBH5MAPTALDH1A1KMT2AHTT | |
| SCHEMBL4023307 | 0.78 | MAPT (0.57) | ALKBH5CYP1A2MAPTALDH1A1KMT2A | |
| SCHEMBL34121 | 0.77 | ALDH1A1 (0.68) | ALKBH5MAPTALDH1A1KMT2AHTT | |
| SCHEMBL9150171 | 0.77 | ALDH1A1 (0.68) | ALKBH5MAPTALDH1A1KMT2AHTT | |
| SCHEMBL5425653 | 0.77 | ALDH1A1 (0.68) | ALKBH5MAPTALDH1A1KMT2AHTT | |
| SCHEMBL7893151 | 0.76 | MAPT (0.54) | ALKBH5MAPTALDH1A1KMT2AHTT | |
| SCHEMBL27912588 | 0.76 | ALKBH5 (0.61) | ALKBH5MAPTALDH1A1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| EP-1223944-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6670387-B1 | Thrombocytopenia; hydroxy-1-azo-naphthalene derivatives; 3-hydroxy-4-((2-hydroxy-1-naphthalenyl)azo-)-1-naphthalenesul fonic acid; promoters of thrombopoiesis and megakaryocytopoi esis; enhancing platelet production; agonizing TPO receptor | SMITHKLINE BEECHAM CORPORATION | 2003-12-30 | — | — | US | disclosed |
| US-6552008-B1 | Administering effective amount of a selected azo-pyrazole derivative for therapy of thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1223944-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1156804-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1223944-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| EP-1156804-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001021180-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000035446-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ALKBH5 3890/4885CYP1A2 2320/4885MAPT 4627/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ALKBH5 3890/4885CYP1A2 2320/4885MAPT 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.